Advertisement

Topics

$CALA Updated Results from Phase 1 Study of Telaglenastat (CB-839) to be Presented at ASCO #GU19 11:35AM PST https://globenewswire.com/news-release/2019/02/16/1733533/0/en/Updated-Results-from-Phase-1-Study-of-Telaglenastat-CB-839-to-be-Presented-at-2019-

14:21 EST 16 Feb 2019 | Odi Bruckman

Updated Results from Phase 1 Study of Telaglenastat (CB-839) to be Presented at ASCO 11:35AM PST https://globenewswire.com/news-release/2019/02/16/1733533/0/en/Updated-Results-from-Phase-1-Study-of-Telaglenastat-CB-839-to-be-Presented-at-2019-ASCO-Genitourinary-Cancer-Symposium.html …

Original Article: $CALA Updated Results from Phase 1 Study of Telaglenastat (CB-839) to be Presented at ASCO #GU19 11:35AM PST https://globenewswire.com/news-release/2019/02/16/1733533/0/en/Updated-Results-from-Phase-1-Study-of-Telaglenastat-CB-839-to-be-Presented-at-2019-

NEXT ARTICLE

More From BioPortfolio on "$CALA Updated Results from Phase 1 Study of Telaglenastat (CB-839) to be Presented at ASCO #GU19 11:35AM PST https://globenewswire.com/news-release/2019/02/16/1733533/0/en/Updated-Results-from-Phase-1-Study-of-Telaglenastat-CB-839-to-be-Presented-at-2019-"

Advertisement
Quick Search
Advertisement
Advertisement